Topic: glioblastoma
A phase III trial of enzastaurin for treatment of recurrent glioblastoma was stopped after an interim analysis showed it did not outperform lomustine. Reuters Health Information ... morePfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diag ... more
Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diag ... more
Cancer researchers at UCLA's Jonsson Comprehensive Cancer Center have performed the complete sequencing of the much-studied brain cancer cell line, U87, a discovery that may lead to target ... more
Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Study may result in new and more effective therapies Researchers at UCLA #8217;s Jonsson Comprehensive Can ... more
Success in mice with glioblastoma may someday lead to treatment for people, researchers say Source: HealthDay Related MedlinePlus Topic: Brain Cancer ... more
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumour, also suppress an immune system attack on the disease, scientists from the University of Texas M. D. A ... more
Each subtype has a different response to therapy, which could lead to personalized treatment and raises hopes for improving the currently poor prognosis. Medscape Medical News ... more
The most common form of brain cancer in adults, glioblastoma multiforme, probably is a set of diseases, rather than a single disease, U.S. researchers said on Tuesday. Source: Reuters Health ... more
New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single ... more
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more
Health News of the Day is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce ab ... more
New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single ... more
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more
Contact: Nancy Cawley Jean njean@lifespan.org Lifespan Achieved a 25 percent cure rate for gliobastoma in animal model; call for trials to begin in humans Providence, RI New research at Rhode Island ... more
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer ... more
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer ... more
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours. But a collaboration between researcher ... more
Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours. But a collaboration between researcher ... more
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. An ... more
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. An ... more
Contact: Scott Merville smerville@mdanderson.org 713-792-0661 University of Texas M. D. Anderson Cancer Center M. D. Anderson researchers discover mechanism that helps glioblastomas evade attack HOUST ... more
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists have found. ... more
Immunocellular Therapeutics, a biotechnology company specializing in immune-based cancer treatments, presented Wednesday at the OneMedForum in San Francisco. The Los Angeles-based company discussed it ... more
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more
Geron Corporation (Nasdaq:GERN) announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor si ... more
Geron Corporation (Nasdaq:GERN) announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor si ... more
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more
US researchers have completed two preclinical studies, one on isolated human cells and the other on rodents, that concluded an experimental breast and lung cancer drug shows promise against prostate ... more
US researchers have completed two preclinical studies, one on isolated human cells and the other on rodents, that concluded an experimental breast and lung cancer drug shows promise against prostate ... more
Therasis Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the jo ... more
Therasis Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the jo ... more
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers have found in two preclinical studie ... more
Contact: Aline McKenzie aline.mckenzie@utsouthwestern.edu 214-648-3404 UT Southwestern Medical Center DALLAS Jan. 4, 2010 An experimental drug currently being tested against breast and lung cancer s ... more
Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the journal Nat ... more
Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multifor ... more
Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the journal Na ... more
Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multifor ... more
Biomedical researchers have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multiforme, the type of malignant brain tumor ... more
Two newly discovered genes may act as master control switches in the progression of the most aggressive form of brain cancer, glioblastoma, a study shows. ... more
Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more
In this program, an expert on brain tumors discusses the current perspectives and latest advances in the treatment of glioblastoma multiforme (GBM). Evidence-based guidelines for newly diagnosed as we ... more
Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more
In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the ... more
David Collingridge discusses research articles on prophylactic cranial irradiation for small-cell lung cancer, and the addition of temozolomide to radiotherapy for treating glioblastoma. ... more
Contact: Elizabeth Streich cumcnews@columbia.edu 212-305-3900 Columbia University Medical Center Discovery made using new systems biology method, which enabled the scientists to pinpoint the genes fro ... more
Contact: Zenaida Gonzalez Kotala zkotala@mail.ucf.edu 407-823-6120 University of Central Florida Biomedical researchers at the University of Central Florida have found a protein that could hold the ke ... more
Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of ... more
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® th ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), ... more
MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® th ... more
Cancer researchers developed a tumor-attacking virus that kills brain-tumor cells and blocks tumor blood-vessel growth. The research shows that viruses designed to kill cancer cells -- oncolytic virus ... more
Contact: Oihane Lakar oihane@elhuyar.com 0034-943-363-040 Elhuyar Fundazioa The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunother ... more
By Mike Havrilla, ProActive Newsroom Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille ... more
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketin ... more
Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, announced that the European Medicines Agency adopted a positive opinion on orphan medicinal p ... more
Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, announced that the European Medicines Agency adopted a positive opinion on orphan medicinal ... more
By Mike Havrx ProActive Newsroom Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on ... more
MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more
MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more
MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more
Researchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a nov ... more
Researchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a nov ... more
Researchers report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme using a novel type of imaging called MR spectroscopy coupled wi ... more
By Mike Havrilla MikeHavRx.com NeoPharm (OTC: NEOL.PK) is an emerging bio-pharmaceutical company focused on the development of anti-cancer agents based on two proprietary technology platforms that in ... more
Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblas ... more
MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its pro ... more
Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblas ... more
In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cel ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demo ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demo ... more
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a ... more
The recent death of Senator Ted Kennedy has focused new attention on brain cancer. Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy #8217;s life, is one of the deadli ... more
Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme ... more
Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme ... more
Researchers find that the STAT3 gene regulates the growth of cancer stem cells in the brain cancer Glioblastoma multiforme. This evidence is consistent with the controversial theory that a minority of ... more
Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer. Both are the focus of an intensive effort in the department ... more
Cancer researchers have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain canc ... more
Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell ... more
Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell ... more
A new strategy proposed by researchers at Dartmouth Medical School and Amtek, Hanover, NH may treat tumors that do not respond to conventional treatment. The study, which was published on May 29th in ... more
The brain tumor afflicting Sen. Edward Kennedy -- a glioblastoma -- is the most aggressive form of brain cancer. But scientists have discovered the tumor's vulnerability. They have identified a networ ... more
The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the b ... more
The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the b ... more
Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as g ... more
Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as g ... more
Scientists have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as glioblastoma. ... more
A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more
A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more
A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more
St. Joseph's Hospital and Medical Center in Phoenix has partnered with Castle Biosciences, Inc. to provide the nation's first genomics-based test for patients suffering from glioblastoma multiforme, ... more
St. Joseph's Hospital and Medical Center in Phoenix has partnered with Castle Biosciences, Inc. to provide the nation's first genomics-based test for patients suffering from glioblastoma multiforme, ... more
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumo ... more
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumo ... more
A new biomarker may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib. ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain ... more
The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer va ... more
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer va ... more
Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) reported encouraging data from an ongoing phase 2 trial of XL184 in patients with previously treated glioblastoma multiforme (G ... more
Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) reported encouraging data from an ongoing phase 2 trial of XL184 in patients with previously treated glioblastoma multiforme (G ... more
- An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University ... more
An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of ... more
An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of ... more
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, provided an update ... more
An experimental compound showed good results for months in patients with glioblastoma multiforme, researchers say. After undergoing other treatments, including surgery, chemotherapy and radiation, the ... more
Source: American Cancer Society ... more
New research from the University of Virginia Health System shows that, when combined, two emerging medical technologies hold significant promise for treating the most deadly and devastating form of br ... more
New research from the University of Virginia Health System shows that, when combined, two emerging medical technologies hold significant promise for treating the most deadly and devastating form of br ... more
A new device that delivers high-intensity laser energy into the brain has been cleared for investigational use in patients with glioblastoma multiforme. Medscape Medical News ... more
Eligible patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, are enrolling in the ACT III clinical trial of a vaccine called CDX-110, whic ... more
Eligible patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, are enrolling in the ACT III clinical trial of a vaccine called CDX-110, whic ... more
The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more
The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more
Ongoing ACT III Clinical Research Trial Studies CDX-110 Vaccine; Aimed at Training Immune System to Kill Cancer Cells > NewYork-Presbyterian Hospital, Weill Cornell Medical College and Columbia Uni ... more
The FDA (Food and Drug Administration, USA) approved Avastin (bevacizumab) for patients with GBM (glioblastoma multiforme) whose cancer carries on progressing after standard therapy. GBM is a rapidly ... more
The FDA (Food and Drug Administration, USA) approved Avastin (bevacizumab) for patients with GBM (glioblastoma multiforme) whose cancer carries on progressing after standard therapy. GBM is a rapidly ... more
The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more
David Schiff, M.D., and colleagues at the University of Virginia Cancer Center were key researchers in a large national clinical trial that has resulted in U.S. Food and Drug Administration (FDA) acce ... more
David Schiff, M.D., and colleagues at the University of Virginia Cancer Center were key researchers in a large national clinical trial that has resulted in U.S. Food and Drug Administration (FDA) acce ... more
Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Avastin® (bevacizumab) for people with glioblastoma with progressive disease following prior ... more
Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Avastin® (bevacizumab) for people with glioblastoma with progressive disease following prior ... more
The FDA has approved the drug Avastin to treat a type of brain cancer called glioblastoma that is progressing despite previous treatment with other therapies. ... more
Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with glioblastoma with progressive disease following prior therapy ... more
A new technique that measures vascular normalization on magnetic resonance imaging (MRI) can predict whether or not a patient with recurrent glioma will respond to anti-vascular endothelial growth fac ... more
Intensive treatment with a combination of lomustine, temozolomide and radiotherapy can achieve long-term survival in patients newly diagnosed with glioblastoma, German and Swiss researchers report in ... more
Nanobiotix, an emerging nanomedicine company, announced today that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme ... more
Nanobiotix, an emerging nanomedicine company, announced today that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme ... more
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how ... more
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how ... more
A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with adva ... more
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma - the most common and deadly brain cancer in humans - that closely resembles the develop ... more
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma - the most common and deadly brain cancer in humans - that closely resembles the develop ... more
Researchers have developed a versatile mouse model of glioblastoma -- the most common and deadly brain cancer in humans -- that closely resembles the development and progression of human brain tumors ... more
UC Davis Cancer Center researchers report the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer. The finding, which is published in the January 2009 issue of the Europ ... more
ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, presented preliminary, promising clinical data from a Phase I trial, evaluating ICT-107, the company's dendritic cell-ba ... more
Researchers have discovered a molecule that targets glioblastoma, a highly deadly form of cancer. ... more
Glioblastoma is one of the most common but also most aggressive brain tumors, almost invariably leading to death in a short time. It consists of different cell types and their precursors, complicating ... more
Erlotinib added to temozolomide and radiation therapy does not improve survival in patients with glioblastoma multiforme (GBM), according to a report in the Journal of Clinical Oncology, published Oct ... more
Coaxing a patient #8217;s own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders. But until now, efforts to follow these specially modified ... more
Microvesicles - tiny membrane-covered sacs - released from glioblastoma cells contain molecules that may provide data that can guide treatment of the deadly brain tumor. Researchers have found tumor-a ... more
Scientists in the USA were asked in 2006 to give priority treatment to glioblastoma brain tumours and this week the prestigious Nature magazine carried information from The Cancer Genome Atlas (TCGA) ... more
Researchers are investigating a new approach to gene therapy for brain tumors -- delivering a cancer-fighting gene to normal brain tissue around the tumor to keep it from spreading. They have found th ... more
A new study analyzing gene expression among patients with glioblastomas has found that not all of the common, deadly brain tumors appear the same upon closer examination. The research, directed by ... more
A new study analyzing gene expression among patients with glioblastomas has found that not all of the common, deadly brain tumors appear the same upon closer examination. The research, directed by ... more
A new study analyzing gene expression among patients with glioblastomas has found that not all of the common, deadly brain tumors appear the same upon closer examination. ... more
A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inh ... more
A Collaborative Study by Scientists at the Weizmann Institute of Science and Scientists at Sheba Medical Center, With the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451 Inh ... more
Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") announced the most recent long-term follow-up data, through June 15, 2008, from its prior ... more
Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") announced the most recent long-term follow-up data, through June 15, 2008, from its prior ... more
The Cancer Genome Atlas (TCGA) has reported results from its first comprehensive study which focused on the deadly brain cancer glioblastoma. The findings are reported in the Sept. 4, 2008, advance ... more
The Cancer Genome Atlas (TCGA) has reported results from its first comprehensive study which focused on the deadly brain cancer glioblastoma. The findings are reported in the Sept. 4, 2008, advance ... more
A team including researchers at the HudsonAlpha Institute and Stanford University, together with colleagues from a number of other organizations, has published a comprehensive analysis of genomic var ... more
An array of broken, missing, and overactive genes -- some implicated for the first time -- have been identified in a genetic survey of glioblastoma, the most common and deadly form of adult brain canc ... more
An array of broken, missing, and overactive genes -- some implicated for the first time -- have been identified in a genetic survey of glioblastoma, the most common and deadly form of adult brain canc ... more
A team including researchers at the HudsonAlpha Institute and Stanford University, together with colleagues from a number of other organizations, has published a comprehensive analysis of genomic var ... more
A trio of genomic studies point to specific genes and signaling pathways that characterize 2 human cancers. The results suggest a potential for targeted therapies in glioblastoma multiforme and shed l ... more
Cytopia Limited (ASX:CYT) announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form ... more
Cytopia Limited (ASX:CYT) announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form ... more
An array of broken, missing and overactive genes have been identified in a genetic survey of glioblastoma, the most common and deadly form of adult brain cancer, report scientists. The large-scale com ... more
The Cancer Genome Atlas (TCGA) Research Network, a collaborative effort funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institute ... more
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new bloo ... more
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new bloo ... more
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blo ... more
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blo ... more
Drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. ... more
Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis. ... more
Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis. Although pre-clinical studies indicated therapeutics inhibiting a gro ... more
A dendritic cell vaccine significantly increased time to survival and time to tumor progression in glioblastoma patients, and a correlation was shown between cancer clinical outcome and T cell respons ... more
Findings from a new study provide the first evidence that the T-cell response seen after therapeutic vaccination for glioblastoma multiforme is directly related to the clinical outcome. Reuters Hea ... more
Bradmer Reports Progression Free Survival Data From Previous Phase II Glioblastoma Multiforme Trials
Bradmer Reports Progression Free Survival Data From Previous Phase II Glioblastoma Multiforme Trials
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme have found a correlation between the "intensity" of a patien ... more
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a ... more
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a ... more
Viruses genetically designed to kill cancer cells offer a promising strategy for treating incurable brain tumors such as glioblastoma, but the body's natural defenses often eliminate the viruses befor ... more
Viruses genetically designed to kill cancer cells offer a promising strategy for treating incurable brain tumors such as glioblastoma, but the body's natural defenses often eliminate the viruses befor ... more
Two weeks ago, I testified before Sen. Ted Kennedy €™s HELP Committee on the state of cancer research today. Lance Armstrong, Steve Case, and Elizabeth Edwards were some of the other witnesses. I brou ... more
Cancers will be much more effectively treated when physicians can determine all of the responsible genetic changes in a tumor and how they react and interact in response to specific treatment(s), acco ... more
Cancers will be much more effectively treated when physicians can determine all of the responsible genetic changes in a tumor and how they react and interact in response to specific treatment(s), acco ... more
Preliminary data show that treatment with the experimental compound cediranib improved both progression-free survival and overall survival in patients with recurrent glioblastoma who failed standard t ... more
Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) announced that new data from the Phase 2 ACT II study in glioblastoma multiforme (GBM) suggest that temozolom ... more
Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) announced that new data from the Phase 2 ACT II study in glioblastoma multiforme (GBM) suggest that temozolom ... more
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a p ... more
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a p ... more
BiPar Sciences, Inc. announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. ... more
BiPar Sciences, Inc. announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, ... more
Research using a newly developed algorithm has significantly advanced understanding of the molecular events associated with the most common primary brain tumor in adults, human glioblastoma (GBM). ... more
Research using a newly developed algorithm has significantly advanced understanding of the molecular events associated with the most common primary brain tumor in adults, human glioblastoma (GBM). The ... more
Glioblastomas are the most common and most malignant type of glioma. Healthcare professionals face many challenges in the treatment of glioblastoma as therapy remains largely palliative, and mean leng ... more
Glioblastomas are the most common and most malignant type of glioma. Healthcare professionals face many challenges in the treatment of glioblastoma as therapy remains largely palliative, and mean leng ... more
Lentigen Corporation announced an exclusive licensing agreement with Case Western Reserve University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy for glioblastoma, an aggressive ty ... more
Lentigen Corporation announced an exclusive licensing agreement with Case Western Reserve University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy for glioblastoma, an aggressive ty ... more
The protein CD95 is known to act as a molecular switch that triggers the apoptosis death program in cells. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have ... more
Malignant tumors have usually lost their ability to destroy themselves by programmed cell death, or apoptosis. Therefore, tumors are often resistant to chemotherapy or radiation therapy, whose effect ... more